Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Piroxicam Taj API

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  
Piroxicam Betacyclodextrine Manufacturers in India Suppliers Piroxicam Betacyclodextrine Exporters Distributors Piroxicam Betacyclodextrine api active pharmaceuticals ingredients Piroxicam Betacyclodextrine manufacturers Side Effects bulk drugs raw material Piroxicam Betacyclodextrine companies Side Effects Importers Piroxicam Betacyclodextrine Piroxicam Betacyclodextrine Exporters Piroxicam Betacyclodextrine exporters FDA Piroxicam Betacyclodextrine DMF Symptoms Generic Taj Pharmaceuticals Ltd. active pharmaceutical ingredients suppliers pharmaceutical Piroxicam Betacyclodextrine manufacturing pharmaceutical drugs pharmaceutical intermediates Piroxicam Betacyclodextrine pharmaceutical chemicals pharmaceutical raw materials Piroxicam Betacyclodextrine active pharmaceutical ingredients Piroxicam Betacyclodextrine committee active pharmaceutical ingredients manufacturer Piroxicam Betacyclodextrine Active Pharmaceutical Ingredients manufacturer Piroxicam Betacyclodextrine exporter drug ingredients pharmaceuticals Pharmaceuticals API Manufacturer Piroxicam Betacyclodextrine, Piroxicam Betacyclodextrine manufacturer India, Piroxicam Betacyclodextrine product, Piroxicam Betacyclodextrine products, Api preparation, Certificate of Analysis API manufacturer product, Piroxicam Betacyclodextrine anti ulcer product, Certificate of Origin COA Piroxicam Betacyclodextrine COS Piroxicam Betacyclodextrine, pharmaceutical generic, pharmaceutical drug, medical, Piroxicam Betacyclodextrine pharma healthcare, pharma patents, contract MSDS manufacturing Trader Piroxicam Betacyclodextrine pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Piroxicam Betacyclodextrine expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Piroxicam Betacyclodextrine DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Piroxicam Betacyclodextrine ingredients, api, HIV Piroxicam Betacyclodextrine, tablets, capsules, syrup & protein Piroxicam Betacyclodextrine powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Piroxicam Betacyclodextrine gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Piroxicam Betacyclodextrine WHO, UKMHRA Approval
   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

Pioglitazone left






HOME >> API >> API List 3 >> Piroxicam Betacyclodextrine >> Drug Description

Piroxicam Betacyclodextrine CAS Registry Number 96684-40-1


Piroxicam Betacyclodextrine CAS  Number

Piroxicam-beta-cyclodextrin (PBC), a complex of piroxicam with beta-cyclodextrin, was developed with the aim of improving the hydrosolubility and bioavailability of piroxicam. The complex is more rapidly absorbed, with a consequent reduction in the time of contact of piroxicam with the gastric and duodenal mucosa. It is hoped that the shorter contact time might reduce the local toxicity of piroxicam, but it is also possible that transiently higher local concentrations of the drug might worsen the injury to the gastro-duodenal mucosa. Four studies have been conducted in healthy volunteers in order to investigate the effects of PBC on the gastro-intestinal tract. In 3 of these trials, all of similar design, PBC (containing 20 mg of piroxicam) was compared with piroxicam 20mg and placebo given once daily with assessment of faecal blood loss using the 51Cr-labelled red-cell technique, and endoscopic appearance of gastroduodenal mucosa before and after 28 consecutive days of treatment. One study showed a significant difference in respect of faecal blood loss towards the end of the 4-week study period favouring PBC over piroxicam, while the 2 others showed comparable but non-significant trends in favour of PBC. In a fourth study, 32 non-patient volunteers received either piroxicam 20mg once daily; PBC 20mg equivalence; indomethacin 50mg twice daily; or placebo. The treatment was given double blind for 14 days. Endoscopy was performed and gastric potential differences were measured by neutral observers before and at the end of treatment. There were no significant differences in the endoscopic scores between the active treatment groups. The gastric potential difference showed greater changes with indomethacin and piroxicam than with placebo and PBC.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Piroxicam Betacyclodextrine

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.